New drug targets Hard-to-Treat cancers with PTEN loss
NCT ID NCT04439188
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a drug called GSK2636771 in 35 patients whose cancers have lost a protein called PTEN. The drug blocks a growth signal that these cancers may rely on. Researchers hope to see if it can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GSK2636771 (a PI3K-beta inhibitor)
- What this could lead to
- If it works, this could point toward a treatment for cancers with PTEN loss, offering a new option for patients with advanced or refractory tumors.
- What could go wrong
- This is a small, early-phase trial (35 patients) with no control group. The drug may not shrink tumors or stop growth, and side effects are possible. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Lab-Grown stem cells could speed immune recovery in blood cancer transplants
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors